Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Launched by SEATTLE CHILDREN'S HOSPITAL ·
Trial Information
Current as of October 15, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new type of immunotherapy treatment for children and young adults with certain hard-to-treat solid tumors outside the brain, including liver cancers and other specific tumor types. The treatment uses the patient’s own immune cells, which are taken from their blood and specially modified in the lab to better recognize and attack their cancer. These modified cells are designed to target a protein called glypican-3, often found on these tumors, and are also engineered to help the immune cells grow stronger and safer during treatment.
Children and young adults who have solid tumors that have returned or not responded to previous treatments, and whose tumors have the glypican-3 protein, may be eligible for this study. If chosen, participants will have a blood sample taken to create their personalized treatment. The study will then carefully test how safe and effective this approach is. Since this is an early-stage trial, its main goal is to learn about safety and how well the treatment works, with close monitoring by the medical team. The trial is currently not yet recruiting participants.
Gender
ALL
Eligibility criteria
About Seattle Children's Hospital
Seattle Children's Hospital is a leading pediatric healthcare institution dedicated to advancing the health and well-being of children through innovative clinical research and trials. As a prominent sponsor of clinical studies, the hospital focuses on developing new treatments and therapies that address the unique medical needs of children. With a commitment to excellence, Seattle Children's Hospital collaborates with a network of researchers, healthcare professionals, and academic institutions to ensure rigorous scientific standards and ethical practices in all its clinical investigations. By prioritizing patient safety and scientific integrity, the hospital aims to contribute to the global body of knowledge in pediatric medicine and improve outcomes for children with various health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Colleen Annesley, MD
Study Director
Seattle Children's Hospital
Corinne Summers, MD
Study Director
Seattle Children's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported